Regeneron

Management of cutaneous squamous cell carcinoma (cSCC) is evolving as emerging evidence expands treatment options across the disease spectrum. This symposium will place the C-POST findings in clinical context, examining how high-risk disease is defined and how adjuvant cemiplimab may influence patient care following surgery and radiation therapy. Faculty will review key clinical considerations from diagnosis, through the complete treatment journey, while highlighting the value of timely multidisciplinary coordination and referral. The discussion will also address patient considerations such as shared decision-making, patient preferences, preparation for multimodal treatment and potential side effects, psychosocial support, surveillance, and long-term follow-up.